Formycon has announced that its US filing for its FYB201 ranibizumab biosimilar has been delayed by several months, after the US Food and Drug Administration asked the firm and its licensing partner Bioeq for more information on the application following a manufacturing change.
Coherus BioSciences had recently struck a deal to acquire exclusive rights from Bioeq to commercialize the biosimilar rival to Lucentis in the US, with Coherus planning to launch the product in 2021. (Also see "Coherus Will Launch US Lucentis Biosimilar By 2021" - Generics Bulletin, 14 November, 2019
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?